e-learning
resources
Madrid 2019
Monday, 30.09.2019
Tuberculosis and comorbidities
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Adverse effects of anti-tuberculosis drugs in hemodialysis patients
O. Gordeeva (Moscow, Russian Federation), N. Karpina (Moscow, Russian Federation), R. Vedernikova (Moscow, Russian Federation), I. Schultz (Moscow, Russian Federation), A. Bagdasarian (Moscow, Russian Federation)
Source:
International Congress 2019 – Tuberculosis and comorbidities
Session:
Tuberculosis and comorbidities
Session type:
Thematic Poster
Number:
2980
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
O. Gordeeva (Moscow, Russian Federation), N. Karpina (Moscow, Russian Federation), R. Vedernikova (Moscow, Russian Federation), I. Schultz (Moscow, Russian Federation), A. Bagdasarian (Moscow, Russian Federation). Adverse effects of anti-tuberculosis drugs in hemodialysis patients. 2980
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Adverse effects analysis results during anti-TB treatment among hemodialysis patients
Source: Virtual Congress 2021 – Challenges and advances in the diagnosis and clinical management of tuberculosis
Year: 2021
Adverse anti-tuberculosis drug events and their management
Source: Eur Respir Monogr 2018; 82: 205-227
Year: 2018
Severe adverse effects of antitubercular drugs and patient management
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
Management of adverse drug events in TB therapy
Source: Eur Respir Mon 2012; 58: 167-193
Year: 2012
Adverse effects of second-line drugs during the treatment of multidrug resistant tuberculosis patients
Source: Eur Respir J 2005; 26: Suppl. 49, 650s
Year: 2005
Adverse events in patients with MDR TB, treated by three types of the chemotherapy regimens
Source: International Congress 2019 – Tuberculosis: treatment and management
Year: 2019
Cardiovascular adverse effects during itraconazole therapy
Source: Eur Respir J 2008; 32: 240
Year: 2008
Frequency of adverse reactions to first-line anti-tuberculosis chemotherapy in patients with relapse(RTB)and newly diagnosed tuberculosis(NDTB)
Source: International Congress 2018 – Challenges in tuberculosis care
Year: 2018
Adverse effects in patients receiving therapy for multi-drug resistant tuberculosis in Latvia
Source: Eur Respir J 2003; 22: Suppl. 45, 41s
Year: 2003
Monitoring of antituberculous drugs adverse events during the treatment of multidrug-resistant pulmonary tuberculosis
Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions
Year: 2011
Adverse effects of moxifloxacin during tuberculosis treatment
Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment
Year: 2012
Adverse reactions to antituberculosis chemotherapy: tolerance versus intolerance
Source: Annual Congress 2009 - Tuberculosis: metabolism and comorbidities
Year: 2009
Frequent adverse events during prolonged Bedaquiline treatment on XDR-tuberculosis patients
Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II
Year: 2019
Adverse effects of treatment in HIV-associated tuberculosis patients in Iran
Source: Annual Congress 2011 - Tuberculosis in immunocompromised hosts
Year: 2011
The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients
Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Year: 2019
Adverse effects of chemotherapy in patients with multidrug-resistant tuberculosis with alcohol abuse and without one
Source: International Congress 2018 – Drug-resistant tuberculosis and the sequelae of pulmonary tuberculosis
Year: 2018
Adverse drug reactions and outcomes of tuberculosis treatment using fixed-dose combination (FDC) regimen
Source: Annual Congress 2012 - Tuberculosis: clinical findings I
Year: 2012
Adverse effects of MDR-TB treatment with a standardized regimen: A report from Iran
Source: Annual Congress 2010 - Adverse events of antituberculosis treatment and comorbidities
Year: 2010
Drug lymphocyte stimulation test in the diagnosis of adverse reactions to anti-tuberculosis drugs
Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III
Year: 2008
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept